2022
Jose Salguero-Linares et al.
Robust transcriptional indicators of immune cell death revealed by spatiotemporal transcriptome analyses
Molecular Plant 2022, vol. 15, issue 6
doi: 10.1016/j.molp.2022.04.010
Aurélie A G Gabriel et al.
Genetic Analysis of Lung Cancer and the Germline Impact on Somatic Mutation Burden
JNCI: Journal of the National Cancer Institute 2022, vol. 114, issue 8
doi: 10.1093/jnci/djac087
Laura Thirouard et al.
Identification of a Crosstalk among TGR5, GLIS2, and TP53 Signaling Pathways in the Control of Undifferentiated Germ Cell Homeostasis and Chemoresistance
Advanced Science 2022
doi: 10.1002/advs.202200626
Ramdane Igalouzene et al.
SMAD4 TGF-β–independent function preconditions naive CD8+ T cells to prevent severe chronic intestinal inflammation
Journal of Clinical Investigation 2022, vol. 132, issue 8
doi: 10.1172/jci151020
Marta Lourenço et al.
The gut environment regulates bacterial gene expression which modulates susceptibility to bacteriophage infection
Cell Host & Microbe 2022, vol. 30, issue 4
doi: 10.1016/j.chom.2022.03.014
Caroline Hoffmann et al.
PD-L1 and ICOSL discriminate human Secretory and Helper dendritic cells in cancer, allergy and autoimmunity
Nature Communications 2022, vol. 13, issue 1
doi: 10.1038/s41467-022-29516-w
Mathilde Dura et al.
DNMT3A-dependent DNA methylation is required for spermatogonial stem cells to commit to spermatogenesis
Nature Genetics 2022, vol. 54, issue 4
doi: 10.1038/s41588-022-01040-z
Justine Marsolier et al.
H3K27me3 conditions chemotolerance in triple-negative breast cancer
Nature Genetics 2022, vol. 54, issue 4
doi: 10.1038/s41588-022-01047-6
Ahmed A. Zayed et al.
Cryptic and abundant marine viruses at the evolutionary origins of Earth’s RNA virome
Science 2022, vol. 376, issue 6589
doi: 10.1126/science.abm5847
Yann-Alexandre Vano et al.
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
The Lancet Oncology 2022, vol. 23, issue 5
doi: 10.1016/s1470-2045(22)00128-0